Bristol-Myers Squibb Company (BMY)
| Market Cap | 95.34B |
| Revenue (ttm) | 47.64B |
| Net Income (ttm) | 5.42B |
| Shares Out | 2.04B |
| EPS (ttm) | 2.67 |
| PE Ratio | 17.54 |
| Forward PE | 7.10 |
| Dividend | $2.48 (5.29%) |
| Ex-Dividend Date | Apr 4, 2025 |
| Volume | 8,401,845 |
| Open | 46.93 |
| Previous Close | 47.03 |
| Day's Range | 46.49 - 47.16 |
| 52-Week Range | 39.35 - 63.33 |
| Beta | 0.40 |
| Analysts | Hold |
| Price Target | 58.93 (+25.78%) |
| Earnings Date | Apr 24, 2025 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for BMY stock is "Hold." The 12-month stock price forecast is $58.93, which is an increase of 25.78% from the latest price.
News
Avoid These Dividend Disasters Before It's Too Late
Dividend stocks are facing many big risks. The high interest rates, trade war, and AI revolution could lead to many dividend cuts. I discuss what this all means for dividend investors.
Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline.
Buy 9 Barron's Better Bets (Than T-Bills) From 16 'Safer' May Dividend Dogs
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge div...
Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference.
Buy These 2 Beaten Down Stocks Now Before They Rally
I'm recommending two beaten-down REITs, American Assets Trust and Alexandria Real Estate, as long-term dividend plays with strong fundamentals and well-covered yields. Both stocks face near-term headw...
5 Dirt-Cheap Dividends Paying Up To 7.6%
Is it time to buy the dip on these cheap dividends—which by the way yield between 5.3% and 7.6%?
Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo and Chemotherapy Followed by Adjuvant Opdivo for.
Final Trade: RIO, FCX, X, BMY
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Jim Cramer talks good companies getting pummeled by rising interest rates
'Mad Money' host Jim Cramer talks opportunity stocks as rising interest rates weigh on some equities.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...
Hawaii in $700 million settlement with Bristol-Myers, Sanofi over Plavix warning label
Hawaii said on Friday it entered a $700 million settlement deal with pharmaceutical firm Bristol-Myers Squibb and units of French pharmaceutical company Sanofi in a case about warning labels related t...
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
Dividend Harvesting Portfolio Week 218: $21,800 Allocated, $2,195.04 In Projected Dividends
Earnings season saw strong reports from Microsoft, Apple, Meta, and Amazon, boosting the S&P 500 by 2.75% and the Nasdaq by 2.82%. The Dividend Harvesting Portfolio gained 1.98% this week, with a tota...
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer.
Bristol Myers to invest $40 billion in the US over 5 years, CEO says
Bristol Myers Squibb will spend $40 billion in the US over the next five years, CEO Christopher Boerner wrote in an opinion piece published by Stat News on Monday.
Top 3 Health Care Stocks That May Rocket Higher In April
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Retirement Strategy: 2 Blue Chip Dividends Now Way Too Cheap
Earnings season offers opportunities to buy undervalued blue-chip stocks like Verizon and Bristol Myers Squibb, both yielding 5-7% and trading below historical PE ratios. Verizon's growth in 5G, broad...
We're in a pharma stock pickers market, says Kessef's Len Yaffe
Len Yaffe, Kessef Capital Management, joins 'Fast Money' to talk opportunities in the pharma stock space.
5 Positives From Bristol-Myers Squibb's Q1 2025 Results
Bristol-Myers Squibb's Q1 2025 results confirm that the stock has significant potential upside now. The company's Growth Portfolio showed healthy sales increase, while the non-GAAP EPS surprised posit...
Exclusive: US pharma tariffs would raise US drug costs by $51 bln annually, report finds
A 25% U.S. tariff on pharmaceutical imports would increase U.S. drug costs by nearly $51 billion annually, boosting U.S. prices by as much as 12.9% if passed on, a report commissioned by the industry'...
Bristol-Myers: Undervalued, Delivering Increased 2025 Guidance
Despite recent underperformance, Bristol-Myers' strong cash position, robust pipeline, and strategic acquisitions position it for future growth, making it an undervalued opportunity. BMY's growth port...
Gold Gains 1%; Bristol Myers Squibb Posts Upbeat Results
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 2% on Thursday.
Bristol-Myers Squibb Company (BMY) Q1 2025 Earnings Call Transcript
Bristol-Myers Squibb Company (NYSE:BMY) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Chuck Triano - SVP and Head of IR Chris Boerner - Board Chair and CEO David Elk...
Bristol-Myers Squibb Is A Good Pick
Bristol-Myers Squibb Company is undervalued, trading 30% below its intrinsic value, with a low price-to-free-cash-flow ratio indicating a strong buying opportunity. In the first quarter, Bristol-Myers...